Development of a High-Quality Tag-Free Ubiquitin Production Platform for Preclinical Applications

Monomeric ubiquitin (Ub1−76) has shown immunomodulatory properties in a herpes simplex virus type 1 (HSV-1)-infected mouse model when administered orally, positioning it as a promising biotherapeutic agent. Accordingly, preclinical research requires sufficient, high-quality Ub1−76 material. This study focuses on developing an expression and purification platform for Tag-Free Ub1−76 and its variant Ub1−74. Ubs were expressed in Escherichia coli BL21(DE3) cells, released by sonication, and precipitated in pH 4.5 glacial acetic acid. The pH was set to 5.1, and Ubs were purified by Size-Exclusion Chromatography (SEC); the buffer was exchanged via SEC desalting. Then, a polishing step using cation-exchange chromatography (CEX) was applied, which finalized purification with a second buffer exchange via SEC desalting. We independently produced six batches of Ub1−76 and three batches of Ub1−74 using the proposed platform, yielding 109.07 mg/L for each protein. The Quality Control (QC) of the Ubs met the predefined acceptance criteria: purity by SE-UHPLC (>95.0%), concentration by Bicinchoninic Acid (>1.0 mg/mL), endotoxin content by LAL (<10 EU/mg), integrity by SDS-PAGE (single band), mean deconvoluted intact-mass centroid values (8564.40 Da for Ub1−76 and 8451.73 Da for Ub1−74). The Ubs obtained in this study were similar to a commercial Ub1−76 (Ub1−76 com), which was used as an identity reference. We also used circular dichroism (CD) to compare the secondary structure of Ub1−76 com, Ub1−76, and Ub1−74; all showed similar structures. The expression platform described here provides Tag-Free ubiquitin suitable for preclinical feasibility research and a framework for producing peptide and small-protein biotherapeutic candidates.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-18
DOI
https://doi.org/10.3390/ijms272210364
Primary Topic
Protein purification and stability
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of a High-Quality Tag-Free Ubiquitin Production Platform for Preclinical Applications

Keyla Gómez-Castellano, Sonia Mayra Pérez‐Tapia, Luis Vallejo‐Castillo, Ana Fragozo et al.
International Journal of Molecular Sciences
Protein purification and stability
article

Development of a High-Quality Tag-Free Ubiquitin Production Platform for Preclinical Applications

Keyla Gómez-Castellano, Sonia Mayra Pérez‐Tapia, Luis Vallejo‐Castillo, Ana Fragozo, Juan Carlos Almagro, Ivette Mendoza-Salazar, Said Vázquez‐Leyva, Luis Elizarrarás-Rodríguez, Juan Vargas-Coto
article en

Abstract

Monomeric ubiquitin (Ub1−76) has shown immunomodulatory properties in a herpes simplex virus type 1 (HSV-1)-infected mouse model when administered orally, positioning it as a promising biotherapeutic agent. Accordingly, preclinical research requires sufficient, high-quality Ub1−76 material. This study focuses on developing an expression and purification platform for Tag-Free Ub1−76 and its variant Ub1−74. Ubs were expressed in Escherichia coli BL21(DE3) cells, released by sonication, and precipitated in pH 4.5 glacial acetic acid. The pH was set to 5.1, and Ubs were purified by Size-Exclusion Chromatography (SEC); the buffer was exchanged via SEC desalting. Then, a polishing step using cation-exchange chromatography (CEX) was applied, which finalized purification with a second buffer exchange via SEC desalting. We independently produced six batches of Ub1−76 and three batches of Ub1−74 using the proposed platform, yielding 109.07 mg/L for each protein. The Quality Control (QC) of the Ubs met the predefined acceptance criteria: purity by SE-UHPLC (>95.0%), concentration by Bicinchoninic Acid (>1.0 mg/mL), endotoxin content by LAL (<10 EU/mg), integrity by SDS-PAGE (single band), mean deconvoluted intact-mass centroid values (8564.40 Da for Ub1−76 and 8451.73 Da for Ub1−74). The Ubs obtained in this study were similar to a commercial Ub1−76 (Ub1−76 com), which was used as an identity reference. We also used circular dichroism (CD) to compare the secondary structure of Ub1−76 com, Ub1−76, and Ub1−74; all showed similar structures. The expression platform described here provides Tag-Free ubiquitin suitable for preclinical feasibility research and a framework for producing peptide and small-protein biotherapeutic candidates.

International Journal of Molecular SciencesVol. 27(22)
Secretaría de Ciencia, Humanidades, Tecnología e Innovación (MX), Instituto Politécnico Nacional (MX)
Good health and well-being
Protein purification and stability
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon